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ABSTRACT
Phytosterols are known to reduce plasma cholesterol levels and thereby reduce cardiovascular risk.
Studies conducted on human and animal models have demonstrated that these compounds have also
anti-inflammatory effects. Recently, an experimental colitis model (dextran sulphate sodium-induced) has
shown that pre-treatment with phytosterols decreases infiltration of inflammatory cells and accelerates
mucosal healing. This study aims to understand the mechanism underlying the colitis by analysing the
end-products of the metabolism in distal colon and liver excised from the same mice used in the previous
work. In particular, an unsupervised gas chromatography-mass spectrometry (GC-MS) and NMR based
metabolomics approach was employed to identify the metabolic pathways perturbed by the dextran
sodium sulphate (DSS) insult (i.e. Krebs cycle, carbohydrate, amino acids, and nucleotide metabolism).
Interestingly, phytosterols were able to restore the homeostatic equilibrium of the hepatic and
colonic metabolome.
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Introduction
Inflammatory bowel disease (IBD) is a group of chronic inflamma-
tory conditions affecting the gastrointestinal tract1. Ulcerative col-
itis (UC) and Crohn’s disease (CD), which represent the most
common IBD subtypes, are both characterised by a dysregulated
immune response to commensal flora caused by genetic, environ-
mental, and microbiological factors. However, the accurate aeti-
ology of IBD is still not completely understood2,3. Even though,
the highest incidence rate of IBD has traditionally been reported
in North America and Western Europe, a very recent study reports
that its occurrence is increasing in newly industrialised countries
in Africa, Asia, and South America, including Brazil and Taiwan,
whose societies have become more westernised. These data high-
light the importance of research for prevention of IBD to manage
this complex and costly disease4.
Phytosterols are plant derived sterols, structurally related to
cholesterol. They have been classified into (i) sterols, which have a
double bond in the sterol ring, and (ii) stanols, which conversely
lack a double bond in the sterol ring, thus being saturated mole-
cules. Phytosterols are known for their hypocholesterolaemic5 and
anti-inflammatory properties6,7 that are independent from each
other8. Among the anti-inflammatory studies, a discrete number
of investigations have been conducted in the last years to under-
stand their role on IBD. Experimental IBD models are often used
for this purpose where the trinitrobenzene sulphonic acid (TNBS)
or dextran sodium sulphate (DSS) is employed to generate models
that mime respectively CD and UC. IBD animal models are often
chosen for their robustness and resemblance to human IBD
regarding the disruption of the colonic epithelial layer and the
progressive immune and inflammatory responses9,10. In this frame,
Aldini et al. performed for the first time a longitudinal preventive
and therapeutic study about the role of phytosterols in the pre-
vention/induction and remission of inflammation in an experimen-
tal murine colitis model11. In particular, a commercially available
nutraceutical, based on a mixture of b-sitosterol, campesterol, stig-
masterol, and brassicasterol (Supplementary Figure S1), was
employed in mice with DSS-induced colitis as well as in healthy
mice. The results of such study showed that pre-treatment with
phytosterols reduces the clinical symptoms and exerts a protective
effect on the induced colonic inflammation, decreasing infiltration
of inflammatory cells, and accelerating mucosal healing. These
effects have been related to the phytosterols antioxidant proper-
ties, thus suggesting that they may actually be taken in consider-
ation as potential nutraceutical tool in the management
(prevention/remission) of IBD and other intestinal inflamma-
tory diseases.
From the above study, it was clear that phytosterols play an
important role in restoring the initial structural and biochemical
environment in the gastrointestinal tract of the colitis mice. In
order to better understand the comprehensive metabolic perturb-
ation induced by the phytosterols administration both in colitis
and control mice; we decided to undertake a metabolomic study
on the same mice employed by Aldini et al. The aim of a metabo-
lomic study was to provide a detailed analysis of the metabolites
(substrates and products) in metabolic pathways that are altered
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by a perturbation12. Currently, there are two major analytical tech-
niques employed in the metabolomic field: nuclear magnetic res-
onance (NMR) spectroscopy and mass spectrometry (MS)13–16.
Both techniques have inherent advantages and disadvantages
that can influence the analytical coverage of the metabolome.
Thus, when possible, a combined application of NMR spectroscopy
and MS definitively represents the best approach to get a com-
plete picture of the metabolome under study17. The importance
of a metabolomic approach to evaluate the impact of IBD pathol-
ogies in humans18–23 and animal models24–27 has been widely
proven in the literature. These studies revealed that specific
metabolites, associated with gut microbiota, oxidative stress, and
regulation of energy levels, were significantly altered by DSS
insult. In addition, Karlsson et al.28 found that the DSS-induced
colitis causes major alterations in hepatic fatty acids metabolism
resembling human IBD, suggesting that the model can also be
used for target discovery and validation of hepatic-related meta-
bolic alterations. In this frame, we decided to focus our attention
both on the colon (where the inflammation damage is located) as
well as on the liver (hub of metabolism) of mice, by employing a
combined application of gas chromatography-mass spectrometry
(GC-MS) and NMR based metabolomics to evaluate the effect of
the phytosterol mixture employed.
Materials and methods
Chemicals
Analytical grade chloroform, methanol, trimethylsilyl cyanide
(TMSCN) (99.8%) and C10–C40 all-even alkane mixture were pur-
chased from Sigma-Aldrich (St. Louis, MO). Water used throughout
the study was purified using a Millipore Milli-Q lab water system
(Merck Millipore Corporation, Merck KGaA, Darmstadt, Germany)
equipped with a 0.22mm filter membrane. Administered phytos-
terols were supplied by Solgar (Solgar ItaliaVR MultinutrientVR S.p.A.,
Padova, Italy). The detailed composition of the nutraceutical prep-
aration is reported in Supplementary Table S1.
Animal study
Forty male Balb/c mice (8 weeks old) weighing from 22 to 25 g
(Charles Rivers Laboratories, Calco, Italy) were enrolled. A detailed
description of the intervention, dietary composition, and phytos-
terols mixture can be found in the paper by Aldini et al.11
As shown in Figure 1, the mice were divided into two groups in
the first day of the study; half of the animals received the usual
commercial control diet, while the other half were fed the same
diet enriched with phytosterols preparation. After 14 d, the group
fed the control diet was split into two subgroups: controls (CT),
which continued to receive the same diet, and DSS treated group
(DS) that received drinking water ad libitum containing DSS (MP
Biomedicals, Solon, OH; molecular weight 36,000–50,000) 5% (v/w)
until day 24. Acute colitis was induced by DSS29. At the same
time, also the group fed the phytosterol-containing diet was split
into two subgroups, following exactly the same procedure
described above. Thus, the phytosterols-treated group (PH) and
the colitis phytosterol-fed group (PD) were generated. The mice of
four groups were sacrificed at the end of the experiment and liver
and distal colons were recovered. The organs were extracted and
subjected to a metabolomic study in order to investigate the
effect of a phytosterols mixture on the treated mice. Both liver
and distal colon samples were analysed by GC-MS, while only the
liver samples (more abundant) were further investigated by NMR.
Twenty-four hours before the experiments, food supply was with-
drawn, while water was maintained ad libitum. The animals were
sacrificed by cervical dislocation. The collection of the organs was
obtained at the end of the remission period, in order to evaluate
a steady state of the colitis follow-up period. A liver and colon
sample, for each mouse, were collected and lyophilised. Briefly,
the tissue samples were frozen in Eppendorf vials at 20 C for
almost 1 h. The vials were transferred in the freeze-dryer chamber
of an Edwards Minifast 680 (Norfolk, England) cooled at 20 C
and lyophilised in two steps: a low temperature ramp from 20
to 4 C during 12 h and a steady temperature of 20 C since the
pressure reached 4 102 mbar. After lyophilisation, the chamber
pressure rebalance was done using nitrogen gas.
Ethical statement
The work has been conducted according to the guidelines set
forth by EEC Directive 86/609 on the care and use of experimental
animals. The protocol for the induction of colitis was approved by
the Institutional Ethics Committee of the University of Bologna
(Protocol 22/03/10). All studies involving animals are reported in
accordance with the ARRIVE guidelines (https://www.nc3rs.org.uk/
arrive-guidelines). Animals were housed in a controlled environ-
ment (22–24 C), maintained on a standard 12-h light/dark cycle
(lights on at 07.00 h), and had free access to food and water
throughout the study. The authors confirm that the protocol was
specifically approved by the Institutional Animal Care and Use
Committee (“Comitato Etico Scientifico per la Sperimentazione
Animale”) of the University of Bologna and transmitted to the
Ministry of Health (art. 7–8–9 D. Lgs.116/92).
Metabolite extraction
A dual phase extraction procedure was performed on colon and
liver samples. Basically, a mixture of water, methanol, and chloro-
form in the volume ratio of 1.8:2:2 was added to the lyophilised
samples30,31. About 40mg of liver and 8mg of distal colon were
collected and mixed with about 960 and 800 mL, respectively, of
extracting mixture. Then, a homogenising step was needed to
break up the tissues and let the partition of the metabolites in
the extracting solvents. A FastPrep-24VR (MP Biomedicals,
Eschwege, Germany) tissue homogeniser with specialised Lysing
Matrix beads was employed for this purpose. After this step, the
supernatant was separated from the pellet, which was discarded.
Figure 1. Overview of the study design. A total of 40 male Balb/c mice were
used for the trial. Twenty mice received a control diet and, after 14 days, were
split into two subgroups: Controls (CT) that continued to receive the same diet,
and DSS treated group (DS) that received water containing DSS ad libitum in
order to induce the colitis. The same procedure was employed for the mice fed
the phytosterols-enriched diet.
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The supernatant was centrifuged at 15,000 rpm at 4 C for 15min.
This procedure generated a two-phase extract: the aqueous upper
phase containing hydrophilic metabolites, while apolar metabo-
lites as lipid molecules moved in the organic lower phase.
Proteins and macromolecules were trapped, instead, in the thin
skin-like layer between the two phases. The upper and lower
phases were separated and transferred into different tubes.
Finally, solvents were completely removed from both fractions
using a vacuum concentrator. Only the hydrophilic phase was
considered in this study.
GC-MS-TOF data acquisition
A total of 40mL of final metabolite extract of each sample were
put in a glass insert, dried first in a SpeedVac Concentrator
(Thermo Fisher Scientific Co., Waltham, MA), for 4 h, and then put
in the lyophiliser, overnight. The glass inserts were sealed with air
tight magnetic lids into GC-MS vials and derivatised by addition of
40mL of TMSCN as described, elsewhere32. Derivatisation and
injection were fully automated using a PAL autosampler (AS) with
Robotic Tool Change system (CTC Analytics, Zwingen, Switzerland)
integrated to the GC-MS-TOF (Pegasus BT, LECO Corporation, Saint
Joseph, MI). The GC-MS consisted of an Agilent 7890B GC (Agilent
Technologies, Santa Clara, CA) and a time-of-flight mass spectrom-
eter (LECO Corporation, Saint Joseph, MI). After the addition of
the derivatisation reagent, samples were transferred into the agi-
tator of the AS and incubated at 40 C for 40min at 750 rpm. This
procedure ensures precise derivatisation time and reproducible
sample injections. Immediately after derivatisation, 1 mL of the
derivatied sample was injected in splitless mode into the injection
port. The septum purge flow and purge flow were set to 25 and
15mL/min, respectively. The injection port temperature was set to
250 C. GC separation was performed on a Rxi-5MS 5% Phenyl
95% Dimethylpolysiloxane column (30 m with I.D. 0.25mm and
film thickness 0.25 mm) (Restek, Bellefonte, PA). The initial tem-
perature of the GC oven was set to 40 C and held for 2min, fol-
lowed by heating at 12–320 C min1 and kept for an additional
8min, making the total run time 33.3min. Mass spectra were
recorded in the range of 45–600 m/z with an acquisition rate of
10 spectra/s, and MS detector and ion source were switched off
during the first 6.4min of solvent delay time. The transfer line and
ion source temperature were set to 280 and 250 C, respectively.
Helium (grade 6.0) was used as carrier gas, at a constant flow rate
of 1mL/min. The mass spectrometer was tuned according to man-
ufacturer’s recommendation using perfluorotributylamine (PFTBA).
The AS and GC-MS were controlled using vendor software PAL
Sample Control (CTC Analytics, Zwingen, Switzerland) and
ChromaTOF (LECO Corporation, Saint Joseph, MI), respectively.
Two technical replicates were prepared for each sample (for a
total of 80 samples); they were randomised prior to derivatisation
and GC–MS analysis. In order to monitor the instrument perform-
ance, a blank sample containing only derivatisation reagent, a
quality control (QC) sample (pooled sample), and an alkane mix-
ture standard sample (all even C10–C40 alkanes at 50 mgL1 in
hexane) were injected after every 10 real samples. The raw GC-
TOF-MS data was processed by the ChromaTOF software version
5.03.09.0 (LECO Corporation, Saint Joseph, MI) that deconvolutes
mass spectra and performs peak identification using NIST11 library
(NIST, Gaithersburg, MD). The library search was set to return top
10 hits with EI-MS match of >80% using normal-forward search
and with a mass threshold of 20. Deconvoluted peaks were
aligned across all samples considering a retention time shift allow-
ance of <2 s and the presence of each metabolite in >80% of all
pooled control samples. In this way, final datasets consisting of 53
metabolites for the liver and 32 metabolites for the colon samples
were obtained. The identification computed by the ChromaTOF
was classified according to the levels indicated by the
Metabolomics Standard Initiatives (MSI)33, (i) Level 1 if the peaks
are confirmed using authentic standards, (ii) Level 2 when the
peaks are identified based on their EI-MS match 80 (%) and
retention index (RI) match (±30), and (iii) Level 3 when the peaks
are identified based on their EI-MS match 65 (%). In our case, no
authentic standards were employed and only the metabolites
characterised by EI-MS match 80 (%) were considered for data
analysis. Thus, in this work, Level 3 includes the metabolites that
have EI-MS match 80 (%) but largely differ in RI from the relative
compound available in the NIST library. The detailed list of identi-
fied metabolites is reported in Supplementary Table S2.
NMR data acquisition
For quantitative reasons, only the liver samples could be analysed
by NMR. All dried polar extracts were resuspended in 540 mL of
D2O together with 60mL of 1 M sodium phosphate buffer (pH 7.2)
to give a final buffer concentration of 0.1 M. Samples were vor-
texed briefly and transferred into 5mm NMR tubes for analysis.
One-dimensional 1H-NMR spectra were acquired at 37 C, employ-
ing a 500MHz Varian Unity Inova spectrometer (Lubbock, TX)
equipped with a 5mm 1Hf13C/15Ng triple resonance probe.
1H-NMR spectra of hydrophilic cell extracts were acquired using a
pulse sequence that includes presaturation in order to suppress
the water signal. All the experiments were acquired with a relax-
ation time of 3 s, a pulse width of 3.83 ms, an acquisition time of
1.5 s, 256 scans, and a spectral width of 6999.7 Hz. The assignment
of the main hydrophilic metabolites was done according to the lit-
erature34,35. Chenomx NMR suite software (Chenomx Inc.,
Edmonton, Canada) and the Human Metabolome Database
(HMDB) (University of Alberta, Edmonton, Canada) helped the
assignment. The NMR spectra were processed using iNMR (www.
inmr.net) software and then imported in Matlab (R2015b The
Mathworks Inc., Natick, MA). The NMR regions above 9.5 ppm and
below 0ppm were removed because containing only noise.
Furthermore, regions between 7.67 and 7.72 ppm and between 3.
35 and 3.38 ppm were discarded because of the residual signals of
chloroform and methanol (employed during the extraction pro-
cedure), respectively. Finally, the region between 4.56 and 5.06
was discarded because of the residual water signal. A global align-
ment step was carried out using icoshift36 and choosing the acet-
ate singlet at 1.92 ppm as reference signal.
Data analysis
Data generated from the GC-TOF-MS, were analysed using both
univariate (ANOVA) and multivariate, such as principal component
analysis (PCA)37 approaches. Before the data analysis, some pre-
processing steps were performed. To minimise non-sample related
variations, the final metabolite matrix was normalised using the
norm1 approach where each variable is divided by the sum of all
variables within a sample. In order to perform the PCA, the GC-MS
variables were then mean centred and scaled to unit variance
(autoscaling), while the NMR dataset was mean centred and
pareto-scaled. Basically, autoscaling employs the standard devi-
ation as a scaling factor thus giving all metabolites the same
chance to affect the model, while pareto-scaling employs the
square root of the standard deviation as scaling factor allowing
the large fold changes to be less dominant compared to the
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original data38. Autoscaling is mainly used in metabolic profiling
approach while mean-centring and pareto-scaling are preferred in
case of metabolic fingerprinting in order to weigh down noisy sig-
nals and baseline noise39. PCA was then performed by using PLS
Toolbox version 8.6.1 in Matlab (R2015b The Mathworks Inc.,
Natick, MA) environment. In order to assess if each metabolite’s
concentration significantly differed among the studied groups, a
one-way ANOVA (anova1 function) test was performed. This test
compares the means of two or more groups of data and returns
the p values for the null hypothesis that the means of the groups
are equal; however, it does not provide information about which
pair of groups has statistically different levels of a certain metabol-
ite. Thus, multcompare function, using the Tukey–Kramer correc-
tion, was employed to perform a multiple comparison (post-hoc)
test. Multcompare routine uses the anova1 results to determine
which are the group means significantly different among all the
possible pairwise combinations (CT-PH, CT-DS, CT-PD, PH-DS, PH-
PD, and DS-PD). Thus, p values for all 85 variables of the com-
bined (liver and colon) GC-MS datasets were calculated. Anova1
and multcompare functions were available through a stats toolbox
of Matlab (R2015b The Mathworks Inc., Natick, MA). A p value
below .05 was considered statistically significant. Details about
GC-MS metabolite identification, ANOVA, and multiple comparison
analysis outputs are reported in Supplementary Table S2.
The impact of DSS and the phytosterol mixture on the meta-
bolic pathways was evaluated by employing the pathway and set
enrichment analysis tools of MetaboAnalyst (http://www.
metaboanalyst.ca/MetaboAnalyst/faces/Home.jsp)40. The results are
reported in Supplementary Figure S3.
Results
The 40 mice employed in this study generated 4 groups: controls
(CT), DSS-treated group (DS), PH, and the colitis phytosterol-
treated group (PD). Liver and distal colons were recovered from
each animal and they were both analysed by GC-MS, while only
the liver samples (for quantitative issues) were further investigated
by NMR.
GC-MS metabolomics analysis
The GC-MS data included 53 variables for the liver and 32 varia-
bles for the colon samples. A univariate (one-way ANOVA)
approach was employed to determine the statistically significant
variables. Interestingly, 44 out of 53 variables were found to be
statistically significant (p< .05) for liver and 25 out of 32 variables
were found to be statistically significant for colon (Supplementary
Table S2). Representative GC-MS chromatograms for colon and
liver samples are reported in Supplementary Figure S2.
Distal colon
GC-MS data were submitted to multivariate data analysis to detect
global correlations and differences among the samples. The initial
Figure 2. (A) PCA scores plot and (B) loading plot of the GC-MS data (distal colon). Bi-plot showing PC1 vs. PC2 scores of the PCA model calculated on (C) CT and DS
groups and (D) DS and PD groups (distal colon). Keys: Controls (CT, red), DSS-induced colitis (DS, green), Phytosterols-fed colitis mice (PD, blue), and Phytosterols-fed
control group (PH, light blue).
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matrix submitted to PCA consisted of 10 pooled and 72 real sam-
ples (8 out of 80 samples were discarded because of the poor
quality of the chromatogram) and 32 variables. The pooled sam-
ples were used to monitor the instrument stability. Thus, after
having verified that the pooled samples consistently lay in the
very middle of the score plot, they were removed from the matrix
and the PCA was recomputed. The score plot (Figure 2(A)) shows
a very clear clustering of the studied groups along the Principal
Component 1 (PC1), which accounts for the 34.5% of the total
variance. In particular, the control group (CT) and the group of
healthy mice treated with phytosterols (PH) are almost superim-
posed and lie in the left part of the plot opposed to groups of
colitis mice (DS) and phytosterols-fed colitis mice (PD). PC2 does
not contain information relative to the treatments, but it only
shows the biological variability that characterise this animal
model. The clear separation along PC1 confirms that the induction
of the colitis definitively perturbs the whole metabolic system in
the distal colon tissue25. Furthermore, the proximity of the phytos-
terol-fed groups to the control-diet ones (CT-PH and DS-PD) sug-
gests that the effect of the phytosterols administration does not
significantly affect the colon metabolome neither in healthy nor in
colitis mice. The metabolites responsible for the groups’ separ-
ation are indicated in the loading plot (Figure 2(B)). In order to
identify the potential markers related to the disease, a PCA only
with data from control (CT) and colitis mice (DS) groups was com-
puted (Figure 2(C)). Higher levels of small organic acids (lactic,
benzoic, glycolic, threonic, malic, pyroglutamic, and glyceric),
amino acids (serine, threonine, aspartic acid, and glycine) as well
as a glycolysis precursor (glycerol-3-phosphate) were found in the
inflamed colon of the DS mice. At the same time, control mice
were characterised by higher concentrations of succinic, oxalic,
and ribonic acids as well as scyllo-inositol, uracil, and myo-inositol.
It is also possible to identify the metabolites, and thus the
metabolic pathways, that respond to the phytosterols treatment
on colitis mice. This can be done computing a PCA including only
DS and PD groups. As clearly shown in Figure 2(D), the PD mice
are characterised by lower levels of amino acids (valine, leucine,
threonine, and serine), small organic acids (malic, glyceric, ribonic,
and citric), uracil, ethanolamine, and glycerol-3-phosphate in com-
parison to the DS ones.
Liver
The GC-MS data matrix obtained from liver samples consisted of
70 real samples (10 out of 80 samples were discarded because of
the poor quality of the chromatogram) and 53 variables.
Analogously to the colon analysis, 10 pooled samples were filtered
out after checking the goodness of the instrument stability over
time. Also in this case, the PCA provided interesting results
(Figure 3(A)). PC1, which accounts for the 25.7% of the total vari-
ance, tends to separate the four groups. Thus, differently from
what observed for the colon, where phytosterols-treated samples
were almost superimposable to the phytosterols free ones, liver
metabolism appears more susceptible to the administration of the
sterols mixture employed. Indeed, a gradual shift of the metabo-
lome from the colitis (DS) to the healthy (CT and PH) mice, pass-
ing through the phytosterol-treated (PD) group, is observed. Thus,
the phytosterols seem to help to restore the biochemical equilib-
rium in the hepatic metabolome. As seen for the colon analysis,
PC2 only explains the intra-group variability more than the inter-
group variation. Interestingly, the computation of an additional
PC3 (7.7% of variance explained), allowed us to detect a clear sep-
aration between the phytosterols-treated groups PH and PD and
the control diet ones (CT and DS) (Figure 3(B)). This suggests that
phytosterols administration slightly affects the hepatic metabolism
independently by the presence/absence of the intestinal inflam-
mation. In order to identify the effect of the disease on the liver
metabolome, a PCA only with control (CT) and colitis mice (DS)
groups was computed (Figure 4(A)). The concentration of three
sugars (glucose, sorbitol, and fructose), as well as of gluconic acid
and galactonic acid turned out to be higher in control mice, while
six organic acids (malic, 3-hydroxybutyric, 2-hydroxybutyric, ben-
zoic, hydracrylic, and pentanedioic), four amino acids (serine, gly-
cine, L-threonine, and L-aspartic acid) as well as urea and niacin
showed higher levels in the DS group. To better identify the meta-
bolic pathway of the liver altered by the phytosterols treatment
on colitis mice, a PCA including only DS and PD groups has been
computed. The PCA bi-plot reported in Figure 4(B) indicates that
the glucose, succinic acid, phosphoric acid, and glycerol-3-phos-
phate levels are higher in the PH, while the plant sterols help
to reduce the high levels of 2-hydroxybutyrate (2-HB),
Figure 3. Bi-plot showing (A) PC1 vs. PC2 and (B) PC1 vs. PC3 scores and loadings of the PCA model calculated on all groups of the liver GC-MS data matrix. Keys:
Controls (CT, red), DSS-induced colitis (DS, green), Phytosterols-fed colitis mice (PD, blue), and Phytosterols-fed control group (PH, light blue).
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3-hydroxybutyrate (3-HB), and amino acids (valine, isoleucine,
aspartic acid, glycine, threonine, and serine). Moreover, the
ANOVA results reported in Supplementary Table S2 clearly shows
that phytosterols administration significantly promotes the
increase of glucose in colitis mice compared to the group that did
not receive the diet supplement. Analogously, a significant
reduced accumulation of 3-hydroxybutyric and 2-hydroxybutyric
acid is observed in PD mice compared to the DS ones.
NMR metabolomics analysis
Given the interesting results obtained by the GC-MS analysis and
the availability of the starting material, we decided to undertake
also an NMR-based metabolomic study on the liver samples.
Seventeen metabolites were identified in all the liver samples
(Supplementary Table S3). The use of NMR allows detecting
metabolites, such as the choline and its derivatives, as well as
nucleotides, and nucleosides that are not observable by GC-MS. A
representative NMR spectrum of the liver extracts is shown in
Figure 5. Forty 1 D 1H-NMR spectra were processed and submitted
to PCA. The PCA scores plot displaying the 2 main PCs explained
46.2% of the variance (PC-1 31.4%, PC-2 14.8%) (Figure 6). The
PC1 loading plot shows a decrease in lactate, succinate, alanine,
glucose, and glycogen levels in the liver samples belonging to the
colitis (DS) and phytosterols-fed colitis mice (PD). At the same
time, these groups showed higher levels of glycerophosphocho-
line (GPC), phosphocholine (PC), choline, acetate, 3-HB, adenosine
monophosphate (AMP), formate, and uridine monophosphate
(UMP). Interestingly, a clear trend that goes from the colitis mice
group (DS) to the healthy one (CT) is visible along the PC1. In par-
ticular, livers extract of the phytosterol-treated colitis mice (PD)
are situated exactly in the middle, between the controls and the
colitis mice. This corroborates the GC-MS results described in the
previous section, thus confirming the phytosterols ability to
Figure 4. Bi-plots showing PC1 vs. PC2 scores and loadings of the PCA model calculated on (A) CT and DS groups and (B) DS and PD liver samples. Keys: Controls
(CT, red), DSS-induced colitis (DS, green), Phytosterols-fed colitis mice (PD, blue), and Phytosterols-fed control group (PH, light blue).
Figure 5. 1H-NMR spectrum of a representative control sample along with the signal assignment. Keys: GPC: glycerophosphocholine; PC: phosphocholine; GSH: reduced
glutathione; AMP: adenosine monophosphate; UMP: uridine monophosphate.
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restore the homeostatic equilibrium of the hepatic metabolome.
Two additional PCA were computed to allow a pairwise compari-
son of the studied groups. The first one was performed on healthy
(CT) and DSS-treated (DS) samples (Figure 7(A)) to evaluate the
perturbation caused by the DSS insult on the hepatic metabo-
lome. The PC1 loading plot, reported in Figure 7(B), shows posi-
tive loading values for lactate, alanine, succinate, glucose, and
glycogen thus indicating higher levels of such metabolites in
control group compared to the DS one. On the other hand, an
increase of 3-HB, acetate, choline, PC, GPC, UMP, AMP, and for-
mate characterised the DSS-treated group. Then, in order to
understand the effects of the phytosterols mixture on the DSS-
induced perturbation, a PCA only including PD (phytosterols-fed
colitis mice) and DS samples was performed (Figure 7(C)).
Interestingly, the corresponding PC1 loading plot (Figure 7(D))
closely resembles the one obtained from the CT-DS comparison.
Figure 6. (A) PCA scores plot and (B) loading plot of the 1H-NMR spectra of mice liver extracts. Keys: Controls (CT, red), DSS-induced colitis (DS, green), Phytosterols-
fed colitis mice (PD, blue), and Phytosterols-fed control group (PH, light blue).
Figure 7. (A) PCA based on the pairwise comparison between controls (CT, red) and colitis group (DS, green), and (B) relative loading plot. (C) PCA based on the pair-
wise comparison between colitis mice fed with the phytosterols (PD, blue) and colitis group (DS, green), and (D) relative loading plot.
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This means that the phytosterols administration (PD group) is able
to restore the homeostatic levels of lactate, alanine, succinate, glu-
cose, glycogen, 3-HB, choline, PC, GPC, UMP, and AMP in the liver.
Discussion
Phytosterols anti-inflammatory properties have recently been
tested by Aldini et al. on an IBD mice model. They also found that
the DSS-induced colitis was associated with body weight loss, vis-
ible faecal blood, diarrhoea, and other histopathological changes,
such as ulcerations, polymorphonuclear cells, and mononuclear
cells infiltration, together with a loss of epithelial structures. After
DSS suspension, the remission phase turned out to be significantly
accelerated in phytosterols-fed mice where incipient healing was
observed. The authors concluded that, even if pre-treatment with
phytosterols does not prevent the colitis onset, it definitively
attenuates the morphologic damage while speeding up the muco-
sal healing during the remission phase11. In this study, we have
performed a more in-depth study of the effects caused by the
DSS insult and phytosterols administration at a metabolic level. In
particular, we decided to employ an unsupervised approach, such
as PCA, to explore the various datasets and to find changes in the
metabolic pathways. Significant perturbations in carbohydrate,
fatty acid, amino acids, and nucleotide metabolism as well as in
the tricarboxylic acid (TCA) cycle were observed.
Carbohydrate and fatty acid metabolism
It is well known that the intestinal damage caused by DSS
severely alters the architecture of the colon mucosa. This leads to
a reduced absorption of nutrients25 and subsequent changes in
the energy metabolism. Thus, the organism tends to increase the
glycolysis rate25,35 that is consistent with the observed reduction
of glucose (NMR and GC-MS) and glycogen (NMR) levels in liver
extracts of colitis mice. The up-regulation of the glycolysis process
is also detectable from the increased concentration of lactate in
the inflamed colonic mucosa cells18 that occurs in case of higher
energy need and lack of energy sources under inflammatory con-
ditions41. Interestingly, the phytosterols administration attenuated
the DSS-related effects in the liver. In particular, higher glucose
levels were detected in the liver of phytosterols-fed colitis mice
(PD) livers compared to the untreated colitis mice (DS groups).
The NMR liver analysis showed also a perturbation of phospho-
lipid metabolism, in particular higher levels of choline and its
derivatives (PC and GPC) were observed in DSS-treated mice in
agreement with Dong et al. findings25. PC and GPC are involved
in phospholipids metabolism which controls membrane’s assem-
bly42. Hepatic accumulation of PC is associated with altered lipid
metabolism occurring during the inflammation that characterises
colitis mice. Recent studies found that DSS insult increases liver
lipoprotein lipase expression and reduces both cytochrome P450
and acyl-CoA oxidase expression28,43. This is consistent with the
higher levels of plasmatic cholesterol found by Aldini et al.11 as
well as with the increased acetate concentration in livers of colitis
mice compared to the controls. Indeed, acetate uptake increases
when higher amount of acetyl-CoA, intermediate for synthesis of
cholesterol and fatty acids, is needed44,45. Lower levels of PC and
GPC were detected in phytosterols-fed colitis mice (PD) livers,
showing the protective effects of the phytosterol administration.
The activation of the fatty acid degradation as energy source is
also consistent with the increase of the hepatic levels of 3-HB. 3-
HB belongs to the ketonic bodies groups and an accumulation of
these metabolites occurs when the lipids, and not the glucose,
become the main source of energy for the organism. Moreover,
higher levels of 2-HB were detected in the DS group (GC-MS). 2-
HB is an early marker for impaired glucose regulation that appears
to arise due to increased lipid oxidation and oxidative stress
indeed; it generally appears at high concentrations case of defi-
cient energy metabolism. Interestingly, a significant reduction in
both 2- and 3-HB acids was observed in the phytosterols-fed col-
itis group compared to DS group, confirming, once again, the
beneficial properties of the phytosterols mixture employed in this
study. In addition, by comparing colitis mice (DS) and control (CT)
groups, lower levels of myo-inositol were found in colitis colonic
cells. Previous studies have hypothesised that extensive colonic
inflammation and consequently a continuous high load of oxida-
tive stress is correlated with low level of myo-inositol in the UC
and it is associated with an increased risk of colorectal cancer46. A
slight reduction of myo-inositol decrease was measured in PD
(phytosterols-fed colitis) group compared to the DS (colitis mice)
colon, suggesting the importance of antioxidant properties of phy-
tosterols for UC healing, as previously reported11.
Amino acid metabolism and TCA cycle
In agreement with the outcome of a recent GC-MS based metabo-
lomic study conducted on sera and colon tissues of DSS-induced
colitis mice24, we also detected higher levels of glycine, serine,
and threonine in the inflamed colon of mice (DS) involved in our
study. Threonine, glycine, and serine are extremely interconnected
amino acids that belong to the same metabolic pathway as indi-
cated also by the pathway analysis reported in Supplementary
Figure S3. Indeed, Gu et al. found an up-regulation of the threo-
nine aldolase gene expression in colitis mice. This enzyme cataly-
ses the reaction that produces glycine and acetaldehyde starting
from the L-threonine. Jain et al. reported a correlation between
glycine and a disorder in the glycolysis process, thus representing
a key metabolite in the rapid cell proliferation of tumors47.
Moreover, serine is derived from glycerol-3-phosphate, a glycolysis
intermediate whose level increased in colitis mice48. In addition,
recent studies showed that serine and glycine biosynthesis might
suppress cellular antioxidative capacities and thus supported
colon tumour homeostasis49. Interestingly, the phytosterols-fed
(PD) group showed decreased colonic levels of serine and threo-
nine compared to the DS group, while no significant changes in
glycine concentration was appreciated. The correlation between
UC and Krebs cycle-related molecules was recently investigated by
Azuma et al.19. Six intermediates (citric, fumaric, isocitric, malic,
pyruvic, and succinic acid) were found to be increased in UC
patients compared to the healthy individuals. In agreement with
the cited study, we also found higher levels of malic and citric
acids in the inflamed colons compared to the control group.
Interestingly, phytosterols were able to reduce the up-regulation
of the Krebs cycle induced by the DSS insult, since lower levels of
both acids were detected in the PD mice compared to the
DS group.
Nucleotide (purine and pyrimidine) metabolism
Interestingly, liver extracts from mice with DSS-induced colitis
showed some dysfunctions in the nucleic acid synthesis/degrad-
ation pathways since adenosine 50-monophosphate, adenosine
50-triphosphate, and UMP levels were higher in colitis mice in
agreement with data reported in literature25. Since the liver is the
primary organ for nucleotide synthesis, our observation implies
colitis may cause the degradation of nucleic acids or inhibit the
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synthesis of DNA and RNA, as these metabolites are the basic
structural units of nucleic acids. A restored equilibrium, in this par-
ticular pathway, seems to be generated in the PD group com-
pared to the DSS-treated mice, proving once again the healthy
effect of phytosterol administration on liver homeostasis.
Conclusions
In this exploratory study, a combined GC-MS and NMR-based
metabolomics approach was used to provide further insights into
the phytosterols role in prevention and remission of DSS-induced
colitis. In particular, an unsupervised data analysis approach was
employed to identify the metabolic pathways perturbed by the
colitis and restored by the phytosterols. Indeed, by means of PCA,
we detected a healing trend for the phytosterols-fed mice, for
which the homeostatic equilibrium in key metabolic pathways,
such as glycolysis, Krebs cycle, amino acids, and nucleotide
metabolism seems to be re-established. These findings suggest
that the phytosterols mixture employed in this work may be taken
into consideration as potential nutraceutical tool in the treatment
and prevention of IBDs, thus reducing their growing impact on
the population.
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